Novartis AG (SWX:NOVN)
104.56
+0.42 (0.40%)
Oct 21, 2025, 5:31 PM CET
Novartis AG Revenue
Novartis AG had revenue of $14.84B USD in the quarter ending June 30, 2025, with 15.26% growth. This brings the company's revenue in the last twelve months to $55.19B, up 12.95% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$55.19B
Revenue Growth
+12.95%
P/S Ratio
4.61
Revenue / Employee
$727.25K
Employees
75,883
Market Cap
202.41B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Sandoz Group AG | 8.42B |
Alcon | 7.97B |
Lonza Group AG | 7.09B |
Galenica AG | 4.03B |
Sonova Holding AG | 3.87B |
Galderma Group AG | 3.73B |
Straumann Holding AG | 2.58B |
Novartis AG News
- 2 days ago - Novartis (NVS) Unveils Promising Pluvicto Trial Results at ESMO Congress 2025 - GuruFocus
- 2 days ago - Novartis' Pluvicto shown to reduce risk of progression or death by 28% in prostate cancer - Reuters
- 2 days ago - PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer - GlobeNewsWire
- 4 days ago - Novartis (NVS) Gains EU Support for Scemblix in Leukemia Treatment - GuruFocus
- 4 days ago - Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Benzinga
- 4 days ago - Novartis (NVS) Reports Positive Long-Term Results for Kisqali in Breast Cancer Trial - GuruFocus
- 4 days ago - Novartis (NVS) Gains EMA Support for Scemblix in Treating Chronic Myeloid Leukemia - GuruFocus
- 4 days ago - Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population - GlobeNewsWire